Organometallics
Article
CH3). 13C NMR (100 MHz, CDCl3): δ 160.0, 140.4, 140.1, 135.6,
135.3, 132.3, 131.1, 130.6, 130.0, 129.6, 100.3, 56.3, 51.0, 48.5, 21.1,
18.2. IR (KBr): ν 3375, 2992, 2945, 2874, 1640, 1506, 1467, 1445, 1368,
1266, 1214, 1144, 1014, 853, 772, 731, 575 cm−1. Anal. Calcd for
C19H22ClIN2: C, 51.78; H, 5.03; N, 6.36. Found: C, 51.52; H, 4.91; N,
6.23. HRMS (ESI): m/z calcd for C19H22ClIN2 [M − Cl]+ 405.0828,
found 405.0838.
(1.7 M in toluene, 1.1 mmol) dropwise at room temperature. After the
solution became clear (about 5−10 min), the indenylidene catalyst M1
(1 mmol) was added at once and the reaction vessel was submerged into
a preheated (65 °C) oil bath. The progress of the reaction was
monitored by TLC (cyclohexane/EtOAc, 4/1). After 25 min the
reaction mixture was cooled to room temperature and the solvent was
evaporated. Purification by silica gel chromatography (cyclohexane/
EtOAc, 19/1, followed by cyclohexane/EtOAc, 9/1) yielded a carmine
film. Next, pentane was added and the flask was submerged in an
ultrasound bath for 10 min. Further decantation provided a micro-
crystalline solid which was dried in vacuo.
[1-(2,4,6-Trimethylphenyl)-3-(benzyl)-2-imidazolidinylidene]-
dichloro(3-phenyl-1H-inden-1-ylidene)(tricyclohexylphosphine)-
ruthenium(II) (4). Following the general procedure, 10a (200 mg, 0.580
mmol), potassium tert-amylate (1.7 M in toluene, 339 μL, 0.580 mmol),
M1 (487 mg, 0.527 mmol), and toluene (29 mL) were used. Purification
by silica gel chromatography (cyclohexane/EtOAc, 19/1) yielded 4, as a
carmine microcrystalline solid (280 mg, 56%).
N1-(2-(Isopropylthio)benzyl)-N3-(2,4,6-trimethylphenyl)-4,5-dihy-
dro-1H-imidazol-3-ium Chloride (10c). Following the general
procedure, from N1-(2-(isopropylthio)benzyl)-N2-(2,4,6-
trimethylphenyl)ethane-1,2-diamine (9c; 2.41 g, 7.04 mmol), triethyl
orthoformate (12 mL), and HCl (4 M solution, 3.7 mL) 10c was
obtained as a white powder (2.62 g, 96%), mp 213-215 °C.
1H NMR (400 MHz, CDCl3): δ 9.43 (s, 1H, Imd-H), 7.72 (d, 1H, J =
8.0, ArH), 7.47 (d, 1H, J = 4.0, Ar-H), 7.38−7.29 (m, 3H, Ar-H), 6.91 (s,
2H, Mes-H), 5.33 (s, 2H, CH2), 4.09 (s, 4H, ImdCH2), 3.45−3.38 (m,
1H, iPr-H), 2.30 (s, 6H, Mes-CH3), 2.26 (s, 3H, Mes-CH3), 1.29−1.28
(d, 6H, J = 4.0, iPr-H). 13C NMR (100 MHz, CDCl3): δ 159.6, 140.4,
136.1, 130.5, 135.5, 134.0, 132.9, 132.0, 130.7, 130.0, 128.2, 51.1, 50.9,
48.3, 39.4, 23.2, 21.1, 18.2. IR (KBr): ν 3147, 2959, 2909, 2863, 2751,
2604, 2580, 2502, 2036, 1678, 1639, 1588, 1515, 1485, 1471, 1443,
1370, 1262, 1218, 1203, 1139, 1064, 1042, 1003, 844, 776, 747, 685, 572,
474 cm−1. Anal. Calcd for C22H29ClN2S: C, 67.93; H, 7.51; N, 7.20.
Found: C, 67.78; H, 7.44; N, 7.16. HRMS (ESI): m/z calcd for
C22H29ClN2S [M − Cl]+ 353.2051, found 353.2065.
1H NMR (400 MHz, CD2Cl2): δ 8.41 (d, 1H, J = 8.0, Ar-H), 7.81 (d,
2H, J = 8.0, Ar-H), 7.71 (d, 2H, J = 8.0, Ar-H), 7.52 (t, 1H, J = 8.0, Ar-H),
7.48−7.38 (m, 5H, Ar-H), 7.25−7.22 (m, 1H, Ar-H), 7.18−7.15 (m, 2H,
Ar-H), 7.04 (d, 1H, J = 8.0, Ar-H), 6.39 (s, 1H, Mes-H), 6.00 (s, 1H,
Mes-H), 5.73−5.60 (m, 2H, CH2), 3.76−3.60 (m, 4H, Imd-CH2),
2.41−2.30 (m, 3H, Cy), 2.10 (s, 3H, Mes-CH3), 2.00 (s, 3H, Mes-CH3),
1.87 (s, 3H, Mes-CH3), 1.83−1.67 (m, 7H, Cy), 1.59−1.47 (m, 12H,
Cy), 1.39−1.26 (m, 7H, Cy), 1.14−1.01 (m, 7H, Cy), 0.97−0.83 (m,
6H, Cy). 13C NMR (100 MHz, CD2Cl2): δ 291.5, 217.0, 216.4, 144.5,
141.2, 138.1, 137.7, 137.5, 137.4, 137.3, 137.2, 136.5, 136.3, 129.9, 129.4,
129.2, 129.1, 129.0, 128.8, 128.4, 128.2, 127.7, 126.9, 116.6, 52.6, 48.8,
34.6, 33.0, 32.9, 30.0, 28.4, 28.3, 28.2, 27.1, 22.9, 21.3, 18.7, 18.6. 31P
NMR (162 MHz, CD2Cl2): δ 35.08. IR (KBr): ν 3053, 2920, 2849,
1488, 1444, 1354, 1266, 1224, 846, 775, 753, 699 cm−1. Anal. Calcd for
C52H65Cl2N2PRu: C, 67.81; H, 7.11; Cl, 7.70; N, 3.04. Found: C, 67.90;
H, 7.36; Cl, 7.74; N, 3.06. HRMS (ESI): m/z calcd for
C52H6535Cl2N2P102Ru [M − Cl]+ 885.3629, found 885.3623.
N1-(2,3,4,5,6-Pentafluorobenzyl)-2-(perfluorophenyl)-N3-(2,4,6-
trimethylphenyl)imidazolidine (13). To a stirred solution of
pentafluorobenzaldehyde (11; 1.28 g, 6.42 mmol) in MeOH (15 mL)
was added PTSA (ca. 5−7 mg). Next, N1-(2,3,4,5,6-pentafluorobenzyl)-
N3-(2,4,6-trimethylphenyl)ethane-1,2-diamine (12; 2.30 g, 6.42 mmol)
was added and, the mixture was stirred at room temperature for 4 h. The
progress of the reaction was monitored by TLC analysis (cyclohexane/
EtOAc, 4/1). Purification by silica gel chromatography (cyclohexane/
EtOAc, 4/1) yielded 13 as a white powder (3.20 g, 93%), mp 100−102
°C.
1H NMR (400 MHz, CDCl3): δ 6.79 (s, 2H, Mes-H), 5.60 (s, 1H,
CH-Imd), 3.84−3.70 (m, 2H, CH2− and 1H, Imd-CH2), 3.34−3.39 (m,
1H, Imd-CH2), 3.25−3.20 (m, 1H, Imd-CH2), 3.17−3.10 (m, 1H, Imd-
CH2) 2.20 (s, 9H, Mes-CH3). 13C NMR (100 MHz, CDCl3): δ 139.9,
136.1, 75.4, 52.2, 51.2, 42.5, 20.9, 18.7. 19F NMR (376 MHz, CDCl3): δ
−143.3 (dd, 2F, J = 24.0, 8.0, Ar-F), −154.9 to −154.6 (m, 2F, Ar-F),−
162.1 to −162.0 (m, 2F, Ar-F). IR (KBr): ν 3002, 2934, 2920, 2876,
2829, 2723, 2417, 1716, 1652, 1501, 1388, 1339, 1308, 1189, 1132,
1042, 1001, 957, 931, 908, 871, 846, 768, 656, 623, 580. Anal. Calcd for
C25H18F10N2: C, 55.93; H, 3.24; N, 5.21. Found: C, 55.98; H, 3.38; N,
5.22. HRMS (ESI): m/z calcd for C25H18F10N2 [M − C6F5]+ 369.1390,
found 369.1387.
[1-(2,4,6-Trimethylphenyl)-3-(2-iodobenzyl)-2-imidazolidinyl-
idene]dichloro(3-phenyl-1H-inden-1-ylidene)(tricyclohexylphos-
phine)ruthenium(II) (5). Following the general procedure, 10b (220
mg, 0.5 mmol), potassium tert-amylate (1.7 M in toluene, 294 μL, 0.5
mmol), M1 (419 mg, 0.454 mmol), and toluene (30 mL) were used.
Purification by silica gel chromatography (cyclohexane/EtOAc, 19/1),
yielded 5 as a cherry red microcrystalline solid (260 mg, 55%).
1H NMR (400 MHz, CD2Cl2): δ 8.41 (d, 1H, J = 8.0, Ar-H), 8.26 (d,
1H, J = 4.0, Ar-H), 7.95 (d, 1H, J = 8.0, Ar-H), 7.72 (d, 2H, J = 8.0, Ar-
H), 7.55−7.38 (m, 5H, Ar-H), 7.26−7.04 (m, 6H, Ar-H), 6.40 (s, 1H,
CH2), 6.32 (s, 1H, CH2), 3.72−3.69 (m, 4H, Imd-CH2), 2.39−2.33 (m,
3H, Cy) 2.13 (s, 3H, Mes-CH3), 2.02 (s, 3H, Mes-CH3), 1.88 (s, 3H,
Mes-CH3), 1.83−1.50 (m, 22H, Cy), 1.38−1.27 (m, 8H, Cy), 1.13−
0.84 (m, 15H, Cy). 13C NMR (100 MHz, CD2Cl2): δ 291.6, 217.6,
216.9, 144.2, 141.0, 139.8, 138.2, 138.1, 137.5, 137.4, 137.1, 137.0, 136.9,
136.3, 130.4, 129.4, 129.4, 129.0, 128.9, 128.8, 128.3, 128.0, 127.6, 126.7,
116.5, 100.6, 60.3, 52.6, 52.5, 48.9, 48.9, 33.0, 32.8, 29.8, 28.2, 28.1, 28.0,
27.9, 27.3, 26.9, 21.0, 18.6, 18.5. 31P (162 MHz, CD2Cl2): δ 34.37. IR
(KBr): ν 3052, 2923, 2847, 1703, 1487, 1444, 1267, 1011, 847, 774, 753,
697 cm−1. Anal. Calcd for C52H64Cl2N2IPRu: C, 59.66; H, 6.16; N, 2.68.
Found: C, 61.16; H, 6.24; N, 2.52 (although these results are outside the
range viewed as establishing analytical purity, they are provided to
illustrate the best values obtained to date). HRMS (ESI): m/z calcd for
C52H6435Cl2N2IP102Ru [M − Cl]+ 1011.2595, found 1011.2585.
[1-(2,4,6-Trimethylphenyl)-3-(2-thioisopropylbenzyl)-2-imidazo-
lidinylidene]dichloro(3-phenyl-1H-inden-1-ylidene)(tricyclohexyl-
phosphine)ruthenium(II) (6). Following the general procedure, 10c
(200 mg, 0.514 mmol), potassium tert-amylate (1.7 M in toluene, 316
μL, 0.538 mmol), M1 (431 mg, 0.467 mmol), and toluene (30 mL) were
used. Purification by silica gel chromatography (cyclohexane/EtOAc,
19/1) yielded 6 as a cherry red microcrystalline solid (224 mg, 48%).
1H NMR (400 MHz, CD2Cl2): δ 8.43 (d, 1H, J = 7.2, Ar-H), 8.27 (d,
1H, J = 7.2, Ar-H), 7.71 (d, 2H, J = 8.0, Ar-H), 7.58−7.51 (m, 2H, Ar-H),
7.45−7.33 (m, 4H, Ar-H), 7.26−7.05 (m, 3H, Ar-H), 7.04 (d, 1H, J =
8.0, Ar-H), 6.40 (s, 1H, CH2), 6.00 (s, 1H, CH2), 3.70−3.64 (m, 4H,
N1-(2,3,4,5,6-Pentafluorobenzyl)-N3-(2,4,6-trimethylphenyl)-4,5-
dihydro-1H-imidazol-3-ium Tetrafluoroborate (14). Following the
general procedure, from N1-(2,4,6-trimethylphenyl)-N2-(2,3,4,5,6-
pentafluorobenzyl)-1,2-diaminoethane (12; 6.10 g, 17 mmol), triethyl
orthoformate (15 mL), and NH4BF4 (2.21 g, 20.4 mmol) 14 was
obtained as a white powder (5.30 g, 68%), mp 220−222 °C.
1H NMR (400 MHz, DMSO-d6): δ 8.99 (s, 1H, CH-Imd), 7.05 (s,
1H, Mes-H), 4.94 (s, 2H, CH2−), 4.20−4.06 (m, 4H, Imd-CH2), 2.27
(s, 3H, Mes-CH3), 2.24 (s, 6H, Mes-CH3). 13C NMR (100 MHz,
DMSO-d6): δ 159.4, 139.5, 135.4, 131.0, 129.4, 50.9, 48.3, 39.5, 20.5,
17.1. 19F NMR (376 MHz, DMSO-d6): δ −143.30 (dd, 2F, J = 24.0, 8.0,
Ar-F), −148.50 (s, 3F, BF4), −153.95 (t, 1F, J = 22.0, Ar-F), −162.20 to
−162.10 (m, 2F, Ar-F). IR (KBr): ν 3090, 2962, 1646, 1513, 1452, 1372,
1338, 1301, 1276, 1223, 1183, 1126, 1068, 964, 924, 854, 761, 626, 571.
Anal. Calcd for C19H18BF9N2: C, 50.03; H, 3.98; N, 6.14. Found: C,
49.76; H, 3.87; N, 6.07. HRMS (ESI): m/z calcd for C19H18BF9N2: [M
− BF4]+ 369.1390, found 369.1387.
General Procedure for the Preparation of Precatalysts 4−7. In
a flame-dried Schlenk tube the corresponding imidazolium salt (1.1
mmol) was dried under vacuum at 80 °C for 3 h. Then, toluene was
added under an atmosphere of argon (to obtain concentration of
carbene c = 0.02 mmol/mL), and to the resulting vigorously stirred
suspension of the imidazolium salt was added potassium tert-amylate
2169
dx.doi.org/10.1021/om4009197 | Organometallics 2014, 33, 2160−2171